These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 54944)

  • 21. Fibrin degradation products. A review of structures found in vitro and in vivo.
    Gaffney PJ
    Ann N Y Acad Sci; 2001; 936():594-610. PubMed ID: 11460518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Critical evaluation of new methods for studying fibrin degradation products].
    Prisco D
    Recenti Prog Med; 1989 May; 80(5):263-7. PubMed ID: 2669062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma fibrinogen, fibrinolytic activity and serum fibrinogen/fibrin degradation products in ischaemic heart disease.
    Dube B; Somani PN; Tripathi GK; Dube RK; Bhattacharya SK
    J Assoc Physicians India; 1985 Dec; 33(12):784-5, 787. PubMed ID: 3837002
    [No Abstract]   [Full Text] [Related]  

  • 24. Biological behavior of higher molecular weight products of fibrinolysis.
    Chang ML; Bang NU
    J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond.
    Bini A; Itoh Y; Kudryk BJ; Nagase H
    Biochemistry; 1996 Oct; 35(40):13056-63. PubMed ID: 8855941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of urinary protein C inhibitor to fibrin(ogen) and its binding mechanism.
    Hayashi S; Yamada K
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):153-8. PubMed ID: 8384496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
    Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
    Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
    Lychev VG; Momot AP; Cherkashin GV
    Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nonenzymatic fibrinolysis].
    Dzhurdzhev A; Atanasov K
    Vutr Boles; 1981; 20(3):18-22. PubMed ID: 6455858
    [No Abstract]   [Full Text] [Related]  

  • 30. [alphaC domains of fibrinogen molecules as the structures accelerating fibrin assembly].
    Medved' LV; Gorkun OV; Maniakov VF; Belitser VA
    Mol Biol (Mosk); 1986; 20(2):461-70. PubMed ID: 3702870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma.
    Koppert PW; Kuipers W; Hoegee-de Nobel B; Brommer EJ; Koopman J; Nieuwenhuizen W
    Thromb Haemost; 1987 Feb; 57(1):25-8. PubMed ID: 2438796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinogen/fibrin in atherogenesis.
    Smith EB; Thompson WD; Crosbie L; Stirk CM
    Eur J Epidemiol; 1992 May; 8 Suppl 1():83-7. PubMed ID: 1387095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 34. [The fibrinogen-fibrin-fibrinolysis system in rheumatoid arthritis].
    Belitskaia GA; Palienko IA; Shevchenko LI; Fedorova NE
    Vrach Delo; 1989 Jan; (1):47-50. PubMed ID: 2718445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
    Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
    Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative study of immunological determination of fibrin and its degradation products. (2)].
    Yasuda J; Tabara C; Hidano M; Mizuno Y; Kazama M
    Rinsho Byori; 1974 Oct; 22(10 Suppl):110. PubMed ID: 4475720
    [No Abstract]   [Full Text] [Related]  

  • 37. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.
    Brenner B; Francis CW; Marder VJ
    J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrin and fibrinogen proteolysis products: comparison between gel filtration and SDS polyacrylamide electrophoresis analysis.
    Alkjaersig N; Davies A; Fletcher A
    Thromb Haemost; 1977 Aug; 38(2):524-5. PubMed ID: 145666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.